About
Biosimilar Therapeutic Monoclonal Antibodies
Areas of Focus
Categories
BiosimilarsAntibodyMiddle East
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
11
As Collaborator
0
Total Enrollment
1,974
By Phase
PHASE3: 6EARLY_PHASE1: 1PHASE1: 1
By Status
COMPLETED: 10UNKNOWN: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT06137092Lead Sponsor
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
PHASE3Completed
50 participants
Started: Jul 22, 2023 · Completed: Sep 27, 2023
NCT04789954Lead Sponsor
Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors
EARLY_PHASE1Completed
14 participants
Started: Dec 29, 2020 · Completed: Jul 31, 2022
NCT03935334Lead Sponsor
Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors
PHASE3Completed
48 participants
Started: Jul 23, 2018 · Completed: Feb 3, 2021
NCT03293108Lead Sponsor
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
PHASE3Unknown
190 participants
Started: Apr 29, 2017 · Completed: Sep 30, 2020
NCT03079063Lead Sponsor
Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
PHASE3Completed
24 participants
Started: Mar 1, 2017 · Completed: Jan 28, 2021
Locations (1)
Headquarters
Tehran, Iran
Map
Loading map...